WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal ...

Cencora has acquired an interest in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in the company.

Pharmaceuticals announced the appointment of Reginald Sanders to its Board of Directors. Sanders is a distinguished retina ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant ...

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

of retina specialists. Cencora (COR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Drug distributor Cencora raised its annual adjusted profit forecast on Thursday, citing benefits from its $4.4 billion takeover of Retina Consultants of America (RCA) and continued strong performance ...

of retina specialists. Cencora has acquired an interest in RCA of approximately 85%, with certain RCA physicians and members of the management team retaining a minority equity interest in the company.

Ip said about 50% of responders to an American Society of Retina Specialists survey reported that they were not treating patients with NPDR without visual acuity loss and without macular edema.

Matika Bio partners with Childs Cure to develop gene therapy vectors for children Matika Bio collaborates with Childs Cure to ...